

Serology-informed estimates of SARS-COV-2 infection fatality risk in Geneva, Switzerland

Javier Perez-Saez^{1,2}, Stephen A Lauer¹, Laurent Kaiser^{3,4,5}, Simon Regard^{6,7}, Elisabeth Delaporte⁷, Idris Guessous^{5,8}, Silvia Stringhini^{5,8,*}, Andrew S Azman^{1,2,*} for the Serocov-POP Study Group[^]

1. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, USA
2. Institute of Global Health, Faculty of Medicine, University of Geneva, Switzerland
3. Geneva Center for Emerging Viral Diseases and Laboratory of Virology, Geneva University Hospitals, Switzerland
4. Division of Laboratory Medicine, Geneva University Hospitals, Switzerland
5. Faculty of Medicine, University of Geneva, Switzerland
6. Department of Acute Medicine, Division of Emergency, Geneva University Hospitals, Switzerland
7. Cantonal Health Service, General Directorate for Health, Geneva, Switzerland
8. Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Switzerland

The infection fatality risk (IFR) is the average number of deaths per infection by a pathogen and is key to characterizing the severity of infection across the population and for specific demographic groups. To date, there are few empirical estimates of IFR published due to challenges in measuring infection rates.^{1,2} Outside of closed, closely surveilled populations where infection rates can be monitored through viral surveillance, we must rely on indirect measures of infection, like specific antibodies. Representative seroprevalence studies provide an important avenue for estimating the number of infections in a community, and when combined with death counts can lead to robust estimates of the IFR.

We estimated overall and age-specific IFR for the canton of Geneva, Switzerland using age-stratified daily case and death incidence reports combined with five weekly population-based seroprevalence estimates.³ From February 24th to June 2nd there were 5'039 confirmed cases and 286 reported deaths within Geneva (population of 506'765). We inferred age-stratified (5-9, 10-19, 20-49, 50-65 and 65+) IFRs by linking the observed number of deaths to the estimated number of infected individuals from each serosurvey. We account for the delays between infection and seroconversion as well as between infection and death.⁴ Inference is drawn in a Bayesian framework that incorporates uncertainty in seroprevalence estimates (supplement).

Of the 286 reported deaths caused by SARS-CoV-2, the youngest person to die was 31 years old. Infected individuals younger than 50 years experienced statistically similar IFRs (range 0.00032-0.0016%), which increases to 0.14% (95% CrI 0.096-0.19) for those 50-64 years old to 5.6% (95% CrI 4.3-7.4) for those 65 years and older (supplement). After accounting for demography and age-specific seroprevalence, we estimate a population-wide IFR of 0.64% (95% CrI 0.38-0.98).

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Our results are subject to two notable limitations. Among the 65+ age group that died of COVID-19 within Geneva, 50% were reported among residents of assisted care facilities, where around 0.8% of the Geneva population resides. While the serosurvey protocol did not explicitly exclude these individuals, they are likely to have been under-represented. This would lead to an overestimation of the IFR in the 65+ age group if seroprevalence in this institutionalized population was higher than in the general population (supplement). Further, our IFR estimates are based on current evidence regarding post-infection antibody kinetics, which may differ between severe and mild infections. If mild infections have significantly lower and short-lived antibody responses, our estimates of IFR may be biased upwards.⁵

Estimates of IFR are key for understanding the true pandemic burden and for weighing different risk reduction strategies. The IFR is not solely determined by host and pathogen biology, but also by the capacity of health systems to treat severe cases. Despite having among the highest per capita incidence in Switzerland, Geneva's health system accommodated the influx of cases needing intensive care (peak of 80/110 ICU-beds including surge capacity) while maintaining care quality standards. As such, our IFR estimates can be seen as a best-case scenario with respect to health system capacity. Our results reveal that population-wide estimates of IFR mask great heterogeneity by age and point towards the importance of age-targeted interventions to reduce exposures among those at highest risk of death.

References

- 1 Russell TW, Hellewell J, Jarvis CI, *et al.* Estimating the infection and case fatality ratio for coronavirus disease (COVID-19) using age-adjusted data from the outbreak on the Diamond Princess cruise ship, February 2020. *Eurosurveillance*. 2020; **25**. DOI:10.2807/1560-7917.es.2020.25.12.2000256.
- 2 Meyerowitz-Katz G, Merone L. A systematic review and meta-analysis of published research data on COVID-19 infection-fatality rates. DOI:10.1101/2020.05.03.20089854.
- 3 Stringhini S, Wisniak A, Piumatti G, *et al.* Repeated seroprevalence of anti-SARS-CoV-2 IgG antibodies in a population-based sample from Geneva, Switzerland. DOI:10.1101/2020.05.02.20088898.
- 4 Nishiura H, Klinkenberg D, Roberts M, Heesterbeek JAP. Early Epidemiological Assessment of the Virulence of Emerging Infectious Diseases: A Case Study of an Influenza Pandemic. 2009; published online Aug 31. DOI:10.1371/journal.pone.0006852.
- 5 Takahashi S, Greenhouse B, Rodríguez-Barraquer I. Are SARS-CoV-2 seroprevalence estimates biased? *Open Science Framework*. 2020; published online May 30. 10.31219/osf.io/y3fxt.

^SEROCoV-POP STUDY Group : Silvia Stringhini^{1, 2, 3}, Idris Guessous^{1, 2}, Andrew S. Azman^{4, 5}, Hélène Baysson², Prune Collombet^{1, 2}, David De Ridder², Paola d'Ippolito¹, Yaron Dibner¹, Natalie Francioli¹, Kailing Marcus¹, Chantal Martinez¹, Natacha Noel¹, Francesco Pennacchio¹, Dusan Petrovic^{1, 3}, Attilio Picazio¹, Giovanni Piumatti^{1, 8}, Jane Portier¹, Caroline Pugin¹, Barinjaka Rakotomiarmanana¹, Aude Richard^{1, 4}, Stephanie Schrempft¹, Maria-Eugenia Zaballa¹, Ania Wisniak⁴, Antoine Flahault^{1, 2, 4}, Isabelle Arm Vernez⁹, Olivia Keiser⁴, Loan Mattera¹⁷, Magdalena Schellongova², Laurent Kaiser^{2, 6, 9, 14}, Isabella Eckerle^{2, 6, 9}, Pierre Lescuyer⁶, Benjamin Meyer^{2, 13}, Géraldine Poulain⁶, Nicolas Vuilleumier^{2, 6}, Sabine Yerly^{6, 9}, Sultan Bahta², Jonathan Barbolini², Rebecca Butzberger², Sophie Cattani², Alioucha Davidovic², Antoine Daeniker², Eugénie de Weck¹⁸, Céline Dubas², Joséphine Duc², Céline Eelbode², Benoit Favre², Alice Gilson², Julie Guérin², Lina Hassar², Aurélia Hepner², Francesca Hovagemyan², Melis Kir², Fanny Lombard², Amélie Mach², Eva Marchetti², Soraya Maret², Kourosh Massiha², Virginie Mathey-Doret², Tom Membrez², Natacha Michel², Emmanuelle Mohbat², Hugo-Ken Oulevey², Irine Sakvarelidze², Milena Stimec², Natacha Vincent², Kor-Gaël Toruslu², Nawel Tounsi², Vincent², Manon Will², Alenka Zeballos Valle², François Chappuis^{1, 2}, Delphine Courvoisier¹, Laurent Gétaz^{1, 2}, Mayssam Nehme¹, Febronio Pardo²², Guillemette Violot²³, Sylvie Welker¹, Alison Chiovini¹, Odile Desvachez¹⁶, Benjamin Emery², Acem Gonul¹, Samia Hurst⁷, Gaëlle Lamour²¹, Yasmina Malim¹, Philippe Matute¹, Jean-Michel Maugey²², Aleksandra Mitrovic¹, Didier Pittet¹², Klara M. Posfay-Barbe^{2, 10}, Jean-François Pradeau²², Christiane Rocchia Fine¹, Lilas Salzmänn-Bellard¹, Mélanie Seixas Miranda¹⁵, Michel Tacchino²², Carol Theurillat¹, Sophie Theurillat²¹, Mélissa Tomasini¹, Didier Trono¹¹, Zoé Waldman²

1. Division of Primary Care, Geneva University Hospitals, Geneva, Switzerland
2. Faculty of Medicine, University of Geneva, Geneva, Switzerland
3. University Centre for General Medicine and Public Health, University of Lausanne, Lausanne, Switzerland
4. Institute of Global Health, Faculty of Medicine, University of Geneva, Geneva, Switzerland
5. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA
6. Division of Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland
7. Institut Ethique, Histoire, Humanités, University of Geneva, Geneva, Switzerland
8. Faculty of BioMedicine, Università della Svizzera italiana, Lugano, Switzerland
9. Geneva Center for Emerging Viral Diseases and Laboratory of Virology, Geneva University Hospitals, Geneva, Switzerland
10. Division of General Pediatrics, Geneva University Hospitals, Geneva, Switzerland
11. School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
12. Infection Prevention and Control program and World Health Organization

- (WHO) Collaborating Centre on Patient Safety, Geneva University Hospitals, Geneva, Switzerland
- 13. Centre for Vaccinology, Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland
- 14. Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland
- 15. Division of Diagnostics, Geneva University Hospitals, Geneva, Switzerland
- 16. Division of Women, Children and Adolescents, Geneva University Hospitals, Geneva, Switzerland
- 17. Campus Biotech, Geneva, Switzerland
- 18. Education Structure, University of Geneva, Geneva, Switzerland
- 19. Institute of Social and Preventive Medicine, Bern, Switzerland
- 20. Deutsches Primatenzentrum (DPZ), Göttingen University, Göttingen, Germany
- 21. Human Ressources Departement, Geneva University Hospitals, Geneva, Switzerland
- 22. Information Systems Division, Geneva University Hospitals, Geneva, Switzerland
- 23. Division of Communication, Geneva University Hospitals, Geneva, Switzerland